Format

Send to

Choose Destination
Methods Mol Biol. 2012;890:59-92. doi: 10.1007/978-1-61779-876-4_4.

Easy and efficient protocols for working with recombinant vaccinia virus MVA.

Author information

1
Institute for Infectious Diseases and Zoonoses, University of Munich LMU, Munich, Germany.

Abstract

Modified vaccinia virus Ankara (MVA) is a highly attenuated and replication-deficient strain of vaccinia virus that is increasingly used as vector for expression of recombinant genes in the research laboratory and in biomedicine for vaccine development. Major benefits of MVA include the clear safety advantage compared to conventional vaccinia viruses, the longstanding experience in the genetic engineering of the virus, and the availability of established procedures for virus production at an industrial scale. MVA vectors can be handled under biosafety level 1 conditions, and a multitude of recombinant MVA vaccines has proven to be immunogenic and protective when delivering various heterologous antigens in animals and humans. In this chapter we provide convenient state-of-the-art protocols for generation, amplification, and purification of recombinant MVA viruses. Importantly, we include methodology for rigid quality control to obtain best possible vector viruses for further investigations including clinical evaluation.

PMID:
22688761
DOI:
10.1007/978-1-61779-876-4_4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center